5:52 PM
 | 
Jul 23, 2013
 |  BC Extra  |  Clinical News

InSite reports Phase III blepharitis data

InSite Vision Inc. (OTCBB:INSV) said twice-daily AzaSite Plus and DexaSite dexamethasone for 14 days each missed the primary endpoint of complete resolution of all clinical signs and symptoms of blepharitis at day 15 vs. AzaSite and vehicle, respectively, in the 907-patient Phase III DOUBle trial...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >